![Christopher Kenney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 426 685 $ in data 30/06/2026
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously held positions as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2018 to 2019, the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and the Senior Vice President-Clinical Development at Biotie Therapies LLC from 2013 to 2016.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 07/04/2026 | 7.069 ( 0,01% ) | 426 685 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Direttore Tecnico/Scientifico/R&S | 23/08/2021 |
| Società | Posizione | Fine |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Direttore Tecnico/Scientifico/R&S | 01/12/2020 |
| ACORDA THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2019 |
Biotie Therapies, Inc. | Direttore Tecnico/Scientifico/R&S | 01/01/2016 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Xenon Pharmaceuticals, Inc.
 Xenon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and delivering of therapeutics for neurological & psychiatric disorders | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders | Health Technology |
Biotie Therapies, Inc. |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
